Table 1.

Patient information

Prior systemic therapyLetrozole/ribociclibPretreatment biopsyProgression biopsy
Patient IDAgeReceptor statusPIK3CA/AKT1 status pretreatmentAdjuvantMetastaticBest responseDOTRBPTENRBPTEN
153ER+/PR/HER2PIK3CA E545K, AKT1 WTTamoxifen, anastrozoleNonePR (−32%)8.4++
261ER+/PR/HER2PIK3CA WT, AKT1 E17KNone (de novo metastatic)LetrozoleSD (+13.5%)1.8+++
3a60ER+/PR/HER2PIK3CA E545K, AKT1 WTDocetaxel/cyclophosphamide, anastrozoleCarboplatin/paclitaxel/veliparibSD (−8.1%)8.3+++
4a68ER+/PR+/HER2Not availableTamoxifenLetrozole, fulvestrant, capecitabineNon-CR/non-PDb8.2+++
545ER+/PR+/HER2PIK3CA H1047R, AKT1 WTDoxorubicin/cyclophosphamide/paclitaxel, tamoxifen/leuprolideLetrozole, fulvestrant, taselisibPR (−45.3%)5.5+++
  • Abbreviations: CR, complete response; DOT, duration of treatment; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; WT, wild-type.

  • aExamined also by autopsy.

  • bEvaluable but not measurable per RECIST 1.1.